S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)

Albireo Pharma - ALBO News Today

$20.05
+0.54 (+2.77%)
(As of 10/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$19.00
$20.10
50-Day Range
$16.32
$26.37
52-Week Range
$16.02
$37.63
Volume
310,204 shs
Average Volume
325,536 shs
Market Capitalization
$393.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$53.25
Get Albireo Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALBO and its competitors with MarketBeat's FREE daily newsletter.



ALBO Media Mentions By Week

ALBO Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ALBO
News Sentiment

1.89

0.80

Average
Medical
News Sentiment

ALBO News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ALBO Articles
This Week

1

1

ALBO Articles
Average Week

SourceHeadline
finance.yahoo.com logoAlbireo to Showcase New Data at AASLD The Liver Meeting® 2022
finance.yahoo.com - October 5 at 12:40 PM
MarketBeat logoRobert W. Baird Raises Albireo Pharma (NASDAQ:ALBO) Price Target to $43.00
americanbankingnews.com - September 26 at 3:00 AM
fool.com logoAlbireo Pharma, Inc. (NASDAQ: ALBO)
fool.com - September 24 at 5:08 AM
marketwatch.com logoAlbireo Pharma Shares Rise After Royalty Agreement
marketwatch.com - September 22 at 12:31 PM
finance.yahoo.com logoAlbireo Announces $115 Million Royalty Monetization Agreement with Sagard
finance.yahoo.com - September 22 at 12:31 PM
finance.yahoo.com logoAlbireo to Participate in Guggenheim Nantucket Therapeutics Conference
finance.yahoo.com - September 20 at 4:55 PM
msn.com logoWhy Bilibili Is Trading Lower By Over Around 14%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session
msn.com - September 8 at 4:17 PM
finanznachrichten.de logoAlbireo Pharma, Inc.: Italian Medicines Agency Approves Reimbursed Access to Bylvay (odevixibat) For Patients with All PFIC Types
finanznachrichten.de - September 7 at 9:33 PM
finance.yahoo.com logoItalian Medicines Agency Approves Reimbursed Access to Bylvay® (odevixibat) For Patients with All PFIC Types
finance.yahoo.com - September 6 at 10:20 AM
nasdaq.com logoAlbireo Pharma To Announce ALGS Trial Data This Fall
nasdaq.com - August 30 at 10:24 AM
nasdaq.com logoAlbireo Pharma, Inc. (NASDAQ:ALBO) Analysts Are Reducing Their Forecasts For This Year
nasdaq.com - August 25 at 3:52 AM
benzinga.com logoRecap: Albireo Pharma Q2 Earnings
benzinga.com - August 16 at 8:09 PM
seekingalpha.com logoAlbireo Pharma stock slips ~26% after co cuts FY sales guidance for lead drug Bylvay
seekingalpha.com - August 16 at 3:08 PM
finance.yahoo.com logoAlbireo Reports Q2 2022 Financial Results and Business Update
finance.yahoo.com - August 16 at 9:55 AM
finance.yahoo.com logoDespite Lacking Profits Albireo Pharma (NASDAQ:ALBO) Seems To Be On Top Of Its Debt
finance.yahoo.com - August 12 at 8:48 AM
finance.yahoo.com logoIs Albireo Pharma (ALBO) Outperforming Other Medical Stocks This Year?
finance.yahoo.com - August 11 at 5:47 PM
finance.yahoo.com logoAlbireo Appoints New Members to Board of Directors
finance.yahoo.com - August 10 at 2:03 PM
finance.yahoo.com logoAlbireo to Participate in 2022 Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 3 at 1:09 PM
finance.yahoo.com logoAlbireo to Report Q2 2022 Financial Results on August 15, 2022
finance.yahoo.com - August 1 at 10:27 AM
finance.yahoo.com logoHas Albireo Pharma (ALBO) Outpaced Other Medical Stocks This Year?
finance.yahoo.com - July 25 at 12:13 PM
finance.yahoo.com logoThe Lancet Gastroenterology & Hepatology Publishes Data from Albireo’s Landmark PEDFIC 1 Study of Bylvay® (odevixibat) Treatment in PFIC
finance.yahoo.com - July 6 at 5:41 PM
finance.yahoo.com logoAlbireo to Present at the William Blair Biotech Focus Conference 2022
finance.yahoo.com - June 30 at 8:14 AM
finance.yahoo.com logoAlbireo Pharma, Inc. (NASDAQ:ALBO): When Will It Breakeven?
finance.yahoo.com - June 28 at 4:06 PM
finance.yahoo.com logoAlbireo Announces Presentation of New Data in Pediatric and Adult Liver Diseases
finance.yahoo.com - June 23 at 9:35 AM
finance.yahoo.com logoAlbireo to Present New Data at the EASL International Liver Congress™ 2022
finance.yahoo.com - June 8 at 12:13 PM
finance.yahoo.com logoAlbireo to Present New Data at the 54th Annual Meeting of ESPGHAN
finance.yahoo.com - June 7 at 10:10 AM
finance.yahoo.com logoAlbireo to Participate at Upcoming Investor Conferences
finance.yahoo.com - June 2 at 8:21 PM
finance.yahoo.com logoAlbireo Presented Data in Cholestatic Liver Diseases at Digestive Disease Week (DDW) 2022
finance.yahoo.com - May 23 at 9:52 AM
finance.yahoo.com logoTime To Worry? Analysts Are Downgrading Their Albireo Pharma, Inc. (NASDAQ:ALBO) Outlook
finance.yahoo.com - May 21 at 10:29 AM
finance.yahoo.com logoAlbireo to Participate in the H.C. Wainwright Global Investment Conference 2022
finance.yahoo.com - May 19 at 9:28 PM
seekingalpha.com logoAlbireo stock plunges on disappointing Q1 result
seekingalpha.com - May 17 at 6:44 PM
seekingalpha.com logoAlbireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q1 2022 Results - Earnings Call Transcript
seekingalpha.com - May 17 at 2:54 AM
finance.yahoo.com logoAlbireo Reports Q1 2022 Financial Results and Business Update
finance.yahoo.com - May 16 at 4:53 PM
finance.yahoo.com logoHere's What Albireo Pharma, Inc.'s (NASDAQ:ALBO) Shareholder Ownership Structure Looks Like
finance.yahoo.com - May 15 at 5:46 PM
seekingalpha.com logoAlbireo Pharma Q1 2022 Earnings Preview
seekingalpha.com - May 13 at 8:22 PM
benzinga.com logoAlbireo Pharma's Earnings Outlook
benzinga.com - May 13 at 3:21 PM
finance.yahoo.com logoAlbireo to Report Q1 2022 Financial Results on May 16
finance.yahoo.com - May 9 at 1:32 PM
theglobeandmail.com logoInstrument Name Albireo Pharma Inc Instrument Symbol (ALBO-Q)
theglobeandmail.com - May 7 at 8:38 AM
seekingalpha.com logoAlbireo: A Speculative Play With Upside
seekingalpha.com - May 4 at 10:32 PM
finance.yahoo.com logoInvesting in Albireo Pharma (NASDAQ:ALBO) five years ago would have delivered you a 57% gain
finance.yahoo.com - April 19 at 8:17 AM
finance.yahoo.com logoAlbireo Completes Enrollment in Pivotal Phase 3 ASSERT Study of BylvayTM (odevixibat) in Alagille Syndrome
finance.yahoo.com - March 29 at 9:37 AM
finance.yahoo.com logoHere's Why Albireo Pharma (NASDAQ:ALBO) Can Manage Its Debt Despite Losing Money
finance.yahoo.com - March 5 at 8:36 AM
seekingalpha.com logoAlbireo Pharma GAAP EPS of -$0.57, revenue of $32.52M
seekingalpha.com - March 2 at 11:08 PM
finance.yahoo.com logoAlbireo Reports Q4 and Year-End 2021 Financial Results and Business Update
finance.yahoo.com - March 1 at 5:17 PM
finance.yahoo.com logoAlbireo Pharma (ALBO) Reports Q4 Loss, Tops Revenue Estimates
finance.yahoo.com - March 1 at 5:17 PM
seekingalpha.com logoAlbireo Pharma Q4 2021 Earnings Preview
seekingalpha.com - February 28 at 9:11 PM
finance.yahoo.com logoNoema Pharma Appoints Michael Gutch as Chief Financial Officer
finance.yahoo.com - February 28 at 12:44 PM
finance.yahoo.com logoIs a Surprise Coming for Albireo Pharma (ALBO) This Earnings Season?
finance.yahoo.com - February 28 at 12:44 PM
finance.yahoo.com logoNICE Recommends Albireo’s Bylvay® (odevixibat) for All PFIC Types
finance.yahoo.com - February 22 at 5:06 PM
finance.yahoo.com logoAlbireo to Report Q4 and Year-End 2021 Financial Results on March 1
finance.yahoo.com - February 22 at 5:06 PM
Get Albireo Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALBO and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:ALBO) was last updated on 10/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.